Elecsys EBV IgM
Roche Diagnostics · Decision date Oct 2, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-02 for Elecsys EBV IgM, submitted by Roche Diagnostics of Indianapolis, Indiana, under 510(k) number K260233. The device falls under regulation 866.3235, classification product code LJN, with subsequent product codes LLM and LSE, in the Microbiology specialty and review panel. The application was received 01/26/2026 and reviewed as a traditional 510(k) without third-party review, combination product status or an authorized predetermined change control plan.
SESE indicates 510(k) clearance, not premarket approval. The public record does not describe the assay's components, intended use, performance data or comparison predicate, so the basis for the equivalence finding remains unknown from these sources. A separate FDA listing shows related Roche submissions decided the same day, K260221 for Elecsys EBV EBNA IgG and K260232 for Elecsys EBV VCA IgG, but the record does not state whether these were reviewed together or share a predicate.
No clinical or analytical claims should be inferred from the clearance alone.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260233
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Roche Diagnostics
- Product code
- LJN
- Decision code
- SESE
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Antibody Igm, If, Epstein-Barr Virus.
- Applicant
- Roche Diagnostics
- Product code
- LJN
- FDA device class
- 1
FDA decision timeline
K260233 received
Application receipt date recorded by FDA.
K260233 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Diagnostics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Indianapolis, IN
Sources and methodology
- Original FDA record: K260233
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records